In this Phase I SBIR contract, Nanoparticle Biochem Inc (NBI) proposes to develop commercially viable synthetic methodology for the production of multifunctional gold Nanoparticle-bombesin conjugate. Gold Nanoparticle-bombesin (AuNP-BBN) conjugate is a potential clinical imaging and therapeutic agent for the detection and treatment of GRP receptors over-expressing prostate and breast cancers. Average size of AuNP-BBN nanoconjugates are 14 nm. AuNP-BBN conjugate was developed by the funds from NCI's cancer nanoscience and nanotechnology platform grant and it is licensed to Nanoparticle Biochem Inc. Currently available methodology can yield only 10 mg quantities of AuNP-BBN. Developing a commercially-viable strategy for synthesizing AuNP-BBN nanoconjugate would significantly help in performing preclinical cancer imaging efficacy studies in larger animal models and preclinical toxicity studies.
